Back to results
US 2015/0087696 A1Published application
METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
AssigneeAllergan, Inc.
InventorsHongwen M. Rivers, Lon T. Spada, Michelle Luu
Life of this patent
Estimating the term…
Abstract
The present invention provides an intraocular implant comprising siRNA combined with a excipient effective to retard the initial release of the siRNA from an implant, wherein said siRNA and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said siRNA into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
Claims11
A biodegradable intraocular implant comprising
- an excipient;
- a small interfering RNA (siRNA);
- and
- a poly (D,L lactide-co-glycolide) polymer with a monomer ratio of 75:25 and an inherent viscosity of 0.2 dL/g.
1 more element
A biodegradable intraocular implant consisting essentially of
- an excipient;
- a small interfering RNA (siRNA);
- and
- a poly (D,L lactide-co-glycolide) polymer with a monomer ratio of 75:25 and an inherent viscosity of 0.2 dL/g.
1 more element
Dependencies are inferred from the claim text.